Molecular basis of chronopharmaceutics

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3560-3576

  Ohdo, Shigehiro ^a   Koyanagi, Satoru ^a   Matsunaga, Naoya ^a   Hamdan, Ahmed ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b Pharos University of Alexandria   (Egypt)

Author keywords

Biological clock; Chrono DDS; Chronopharmaceutics; Chronopharmacokinetics; Chronopharmacology; Circadian rhythm; Clock genes

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DILTIAZEM; FAMOTIDINE; HOKUNALIN; LEUCINE ZIPPER PROTEIN; PER1 PROTEIN; PER2 PROTEIN; PROPRANOLOL; PROTEIN BMAL1; SIMVASTATIN; THEOPHYLLINE; TRANSCRIPTION FACTOR CLOCK; TULOBUTEROL; UNCLASSIFIED DRUG; VASCULOTROPIN; VERAPAMIL;

ASTHMA; BIOLOGICAL RHYTHM; CHRONOBIOLOGY; CHRONOPHARMACOKINETICS; CHRONOPHARMACOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SAFETY; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MOLECULAR CLOCK; NONHUMAN; REVIEW; SLEEP DISORDER; SLEEP PARAMETERS; ULCER;

EID: 79960130488     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22656     Document Type: Review

References (109)

1. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. 2010. Clinical pharmacology and pharmacogenetics in a genomics era: The DMET platform. Pharmacogenomics 11:89-103.
2. Zhou SF, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M, Duan W. 2008. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9:738-784.
3. Koster ES, Rodin AS, Raaijmakers JA, Maitland-van derZeeAH 2009. Systems biology in pharmacogenomic research: The way to personalized prescribing?. Pharmacogenomics 10:971-981.
4. Hope WW, Drusano GL. 2009. Antifungal pharmacokinetics and pharmacodynamics: Bridging from the bench to bedside. Clin Microbiol Infect 15:602-612.
5. Xu H, Murray M, McLachlan AJ. 2009. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr Drug Metab 10:643-658.
6. Tei H, Okamura H, Shigeyoshi Y, Fukuhara C, Ozawa R, Hirose M, Sakaki Y. 1997. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature 389:512-516.
7. Halberg F. 1969. Chronobiology. Annu Rev Physiol 31:675-725.
8. Reinberg A, Halberg F. 1971. Circadian chronopharmacology. Annu Rev Pharmacol 11:455-492.
9. Lemmer B, Scheidel B, Behne S. 1991. Chronopharmacokinetics and chronopharmacodynamics of cardiovascular active drugs: Propranolol, organic nitrates, nifedipine. Ann N Y Acad Sci 618:166-181.
10. Smolensky MH, Labrecque G. 1997. Chronotherapeutics. Pharm News 4:10-16.
11. Ohdo S. 2010. Chronotherapeutic strategy: Rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev 62:859-875.
12. Ohdo S, Koyanagi S, Matsunaga N. 2010. Chrono-drug-delivery focused on biological clock: Intra- and inter-individual variability of molecular clock. Adv Drug Deliv Rev 62:885-897.
13. Duncan WC. 1996. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 71:253-312.
14. Moore RY, Eichler VB. 1972. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res 42:201-206.
15. Shigeyoshi Y, Taguchi K, Yamamoto S, Takekida S, Yan L, Tei H, Moriya T, Shibata S, Loros JJ, Dunlap JC. Okamura H. 1997. Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript. Cell 91:1043-1053.
16. Jin X, Shearman LP, Weaver DR, Zylka MJ, de Vries GJ, Reppert SM. 1999. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 96:57-68.
17. Kalsbeek A, van Heerikhuize JJ, Wortel J, Buijs RM. 1996. A diurnal rhythm of stimulatory input to the hypothalamo-pituitary-adrenal system as revealed by timed intrahypothalamic administration of the vasopressin V1 antagonist. J Neurosci 16:5555-5565.
18. Zylka MJ, Shearman LP, Weaver DR, Reppert SM. 1998. Three period homologs in mammals: Differential light responses in the suprachiasmatic circadian clock and oscillating transcripts outside of brain. Neuron 20:1103-1110.
19. Ripperger JA, Shearman LP, Reppert SM, Schibler U. 2000. Clock, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev 14:679-689.
20. Kume K, Zylka MJ, Sriram S, Shearman LP, Weaver DR, Jin X, Maywood ES, Hastings MH, Reppert SM. 1999. mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 98:193-205.
21. Sakamoto K, Nagase T, Fukui H, Horikawa K, Okada T, Tanaka H, Sato K, Miyake Y, Ohara O, Kako K, Ishida N. 1998. Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J Biol Chem 273:27039-27042.
22. Ueyama T, Krout KE, Nguyen XV, Karpitskiy V, Kollert A, Mettenleiter TC, Loewy AD. 1999. Suprachiasmatic nucleus: A central autonomic clock. Nature Neurosci 2:1051-1053.
23. Silver R, LeSauter J, Tresco PA, Lehman MN. 1996. A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. Nature 382:810-813.
24. Beato M, Herrlich P, Schutz G. 1995. Steroid hormone receptors: Many actors in search of a plot. Cell 83:851-857.
25. Balsalobre A, Brown SA, Marcacci L, Tronche F, Kellendonk C, Reicha HM, Schutz G, Schibler U. 2000. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 289:2344-2347.
26. Gekakis N, Staknis D, Nguyen H, Davis F, Wilsbacher L, King D, Takahashi J, Weitz C. 1998. Role of the CLOCK protein in the mammalian circadian mechanism. Science 280:1564-1569.
27. Vitaterna H, Ko H, Chang M, Buhr E, Fruechte E, Schook A, Antoch M, Turek F, Takahashi J. 2006. The mouse clock mutation reduces circadian pacemaker amplitude and enhances efficacy of resetting stimuli and phase-response curve amplitude. Proc Natl Acad Sci U S A 103:9327-9332.
28. Oishi K, Miyazaki K, Kadota K, Kikuno R, Nagase T, Atsumi G, Ohkura N, Azama T, Mesaki M, Yukimasa S, Kobayashi H, Iitaka C, Umehara T, Horikoshi M, Kudo T, Shimizu Y, Yano M, Monden M, Machida K, Matsuda J, Horie S, Todo T, Ishida N. 2003. Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem 278:41519-41527.
29. Miller B, McDearmon E, Panda S, Hayes K, Zhang J, Andrews J, Antoch M, Walker J, Esser K, Hogenesch J, Takahashi J. 2007. Circadian and CLOCK-controlled regulation of the mouse transcriptome and cell proliferation. Proc Natl Acad Sci U S A 104:3342-3347.
30. Ohkura N, Oishi K, Fukushima N, Kasamatsu M, Atsumi G, Ishida N, Horie S, Matsuda J. 2006. Circadian clock molecules CLOCK and CRYs modulate fibrinolytic activity by regulating the PAI-1 gene expression. J Thromb Haemost 4:2478-2485.
31. Kim J, Matsunaga N, Koyanagi S, Ohdo S. 2009. Clock gene mutation modulates the cellular sensitivity to genotoxic stress through altering the expression of N-methylpurine DNA glycosylase gene. Biochem Pharmacol 78:1075-1082.
32. Takahashi J, Hong H, Ko C, McDearmon E. 2008. The genetics of mammalian circadian order and disorder: Implications for physiology and disease. Nat Rev Genet 9:764-775.
33. Ohdo S. 2003. Changes in toxicity and effectiveness with timing of drug administration: Implications for drug safety. Drug Safety 26:999-1010.
34. Ohdo S. 2010. Chronopharmaceutics: Pharmaceutics focused on biological rhythm. Biol Pharm Bull 33:159-167.
35. Jones CR, Campbell SS, Zone SE, Cooper F, DeSano A, Murphy PJ, Jones B, Czajkowski L, Ptacek LJ. 1999. Familial advanced sleep-phase syndrome: A short-period circadian rhythm variant in humans. Nature Med 5:1062-1065.
36. Toh KL, Jones CR, He Y, Eide EJ, Hinz WA, Virshup DM, Ptacek LJ, Fu YH. 2001. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 291:1040-1043.
37. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, Lee ME. 2000. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 275:36847-36851.
38. Shimba S, Ishii N, Ohta Y, Ohno T, Watabe Y, Hayashi M, Wada T, Aoyagi T, Tezuka M, 2005. Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci U S A 102:12071-12076.
39. Takane H, Ohdo S, Yamada T, Yukawa E, Higuchi S. 2000. Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice. J Pharmacol Exp Ther 294:746-752.
40. Ohdo S, Wang DS, Koyanagi S, Takane H, Inoue K, Aramaki H, Yukawa E, Higuchi S. 2000. Basis for dosing time-dependent changes in the antiviral activity of interferon-α in mice. J Pharmacol Exp Ther 294:488-493.
41. Nakagawa H, Takiguchi T, Nakamura M, Furuyama A, Koyanagi S, Aramaki H, Higuchi S, Ohdo S. 2006. Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice. Biochem Pharmacol 72(10):1237-1245.
42. Ohdo S, Makinosumi T, Ishizaki T, Yukawa E, Higuchi S, Nakano S, Ogawa N. 1997. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 283:1383-1388.
43. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. 2003. Control mechanism of the circadian clock for timing of cell division in vivo. Science 302:255-259.
44. Koyanagi S, Kuramoto Y, Nakagawa H, Aramaki H, Ohdo S, Soeda S, Shimeno H. 2003. A molecular mechanism regulating circadian expression of vascular endothelial growth factor in tumor cells. Cancer Res 63:7277-7283.
45. Nakagawa H, Koyanagi S, Takiguchi T, Kuramoto Y, Soeda S, Shimeno H, Higuchi S, Ohdo S. 2004. 24-hour oscillation of mouse methionine aminopeptidase2, a regulator of tumor progression, is regulated by clock gene proteins. Cancer Res 64:8328-8333.
46. Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y, Wang KY, Otsuji Y, Kohno K. 2007. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26(33):4749-4760.
47. Kang TH, Sancar A. 2009. Circadian regulation of DNA excision repair: Implications for chrono-chemotherapy. Cell Cycle 8(11):1665-1667.
48. Antoch MP, Chernov MV. 2009. Pharmacological modulators of the circadian clock as potential therapeutic drugs.2288. Mutat Res 679(1-2):17-23.
49. Desai VG, Moland CL, Branham WS, Delongchamp RR, Fang H, Duffy PH, Peterson CA, Beggs ML, Fuscoe JC. 2004. Changes in expression level of genes as a function of time of day in the liver of rats. Mutation Res 549:115-129.
50. Turek FW, Allanda R. 2002. Liver has rhythm. Hepatology 35:743-745.
51. Yamaguchi S, Mitsui S, Yan L, Yagita K, Miyake S, Okamura H. 2000. Role of DBP in the circadian oscillatory mechanism. Mol Cell Biol 20:4773-4781.
52. Yan L, Miyake S, Okamura H. 2000. Distribution and circadian expression of dbp in SCN and extra-SCN areas in the mouse brain. J Neurosci Res 59:291-295.
53. Lavery DJ, Lopez-Molina L, Margueron R, Fleury-Olela F, Conquet F, Schibler U, Bonfils C. 1999. Circadian expression of the steroid 15 α-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP. Mol Cell Biol 19:6488-6499.
54. Gachon F, Olela FF, Schaad O, Descombes P, Schibler U. 2006. The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab 4:25-36.
55. Murakami Y, Higashi Y, Matsunaga N, Koyanagi S, Ohdo S. 2008. Circadian clock-controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology 135(5):1636-1644.
56. Saito H, Terada T, Shimakura J, Katsura T, Inui K. 2008. Regulatory mechanism governing the diurnal rhythm of intestinal H+/peptide cotransporter 1 (PEPT1). Am J Physiol Gastrointest Liver Physiol 295(2):G395-G402.
57. Matsunaga N, Ikeda M, Takiguchi T, Koyanagi S, Ohdo S. 2008. The molecular mechanism regulating 24-hour rhythm of CYP2E1 expression in the mouse liver. Hepatology 48(1):240-251.
58. Matsunaga N, Nakamura N, Yoneda N, Qin T, Terazono H, To H, Higuchi S, Ohdo S. 2004. Influence of feeding schedule on 24-h rhythm of hepatotoxicity induced by acetaminophen in mice. J Pharmacol Exp Ther 311(2):594-600.
59. Takiguchi T, Tomita M, Matsunaga N, Nakagawa N, Koyanagi S, Ohdo S. 2007. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenet Genomics 17(12):1047-1056.
60. Ohdo S, Koyanagi S, Suyama H, Higuchi S, Aramaki H. 2001. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nature Med 7:356-360.
61. Terazono H, Hamdan AM, Matsunaga N, Hayasaka N, Kaji H, Egawa T, Makino K, Shigeyoshi Y, Koyanagi S, Ohdo S. 2008. Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: A possible mechanism of chemotherapy-induced circadian rhythm disturbances. Biochem Pharmacol 75:1616-1622.
62. Fattovich G, Giustina G, Favarato S, Ruol AA. 1996. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24:38-47.
63. Janssen HLA, Brouwer JT, van der Mast RC, Schalm SW. 1994. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 21:241-243.
64. Bocci V. 1985. Administration of interferon at night may increase its therapeutic index. Cancer Drug Deliv 2:313-318.
65. Damiola F, Le Minh N, Preitner N, Kornmann B, Fleury-Olela F, Schibler U. 2000. Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic neucleus. Genes Dev 14:2950-2961.
66. Boulos Z, Terman M. 1980. Food availability and daily biological rhythms. Neurosci Biobehav Rev 4:119-131.
67. Lohmann CP, Kroher G, Bogenrieder T, Spiegel D, Preuner J. 1999. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. Lancet 353:1326.
68. Purvin VA. 1995. Anterior ischemic optic neuropathy secondary to interferon-α. Arch Ophthalmol 113:1041-1044.
69. Hunter CA, Gabriel KE, Radzanowski T, Neyer LE, Remington JS. 1997. Type I interferons enhance production of IFN-γ by NK cells. Immunol Lett 59:1-5.
70. Lundkvist GB, Robertson B, Mhlanga JD, Rottenberg ME, Kristensson K. 1998. Expression of an oscillating interferon-γ receptor in the suprachiasmatic nuclei. Neuro Report 9:1059-1063.
71. Filipski E, Subramanian P, Carriere J, Guettier C, Barbason H, Levi F. 2009. Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res 680:95-105.
72. Takahashi JS. 1995. Molecular neurobiology and genetics of circadian rhythms in mammals. Annu Rev Neurosci 18:531-553.
73. Akiyama M, Kouzu Y, Takahashi S, Wakamatsu H, Moriya T, Maetani M, Watanabe S, Tei H, Sakaki Y, Shibata S. 1999. Inhibition of light- or glutamate-induced mPer1 expression represses the phase shifts into the mouse circadian locomotor and suprachiasmatic firing rhythms. J Neurosci 19:1115-1121.
74. Horikawa K, Yokota S, Fuji K, Akiyama M, Moriya T, Okamura H, Shibata S. 2000. Nonphotic entrainment by 5-HT1A/7 receptor agonists accompanied by reduced Per1 and Per2 mRNA levels in the suprachiasmatic nuclei. J Neurosci 20:5867-5873.
75. Aschoff J. 1963. Comparative physiology: Diurnal rhythms. Ann Rev Physiol 25:581-600.
76. Krieger DT, Hauser H, Krey LC. 1977. Suprachiasmatic nuclear lesions do not abolish food-shifted circadian adrenal and temperature rhythmicity. Science 197:398-399.
77. Krieger DT. 1980. Ventromedial hypothalamic lesions abolish food-shifted circadian adrenal and temperature rhythmicity. Endocrinology 106:649-654.
78. Honma K, Noe Y, Honma S, Katsuno Y, Hiroshige T. 1992. Roles of paraventricular catecholamines in feeding-associated corticosterone rhythm in rats. Am J Physiol 262:E948-955.
79. Ohdo S, Ogawa N, Nakano S, Higuchi S. 1996. Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J Pharmacol Exp Ther 278(1):74-81.
80. Saito M, Nishimura K, Kato H. 1989. Modifications of circadian cortisol rhythm by cyclic and continuous total enteral nutrition. J Nutr Sci Vitaminol 35:639-647.
81. Labrecque G, Belanger P. 1991. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 52:95-107.
82. Youan BC. 2004. Chronopharmaceutics: Gimmick or clinically relevant approach to drug delivery?. J Control Rel 98:337-353.
83. FDA. 2003. Electronic orange book. Administration, F.a. D. Washington, District of Columbia.
84. Hrushesky WJ, Grutsch JF, Wood P, Yang X, Oh EY, Ansell C, Kidder S, Ferrans C, Quiton DF, Reynolds J, Du-Quiton J, Levin R, Lis C, Braun D. 2009. Circadian clock manipulation for cancer prevention and control and the relief of cancer symptoms. Integr Cancer Ther 8:387-397.
85. Fu L, Pelicano H, Liu J, Huang P, Lee C. 2002. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111(1):41-50.
86. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. 2005. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26(7):1241-1246.
87. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP. 2005. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood 106(8):2827-2836.
88. Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, Al-Assaad Z, Carnevale K, Berger FG, Peña MM, Hrushesky WJ. 2008. Period 2 mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res 6(11):1786-1793.
89. Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP. 2009. A role for the clock gene per1 in prostate cancer. Cancer Res 69(19):7619-7625.
90. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y. 2009. Clock-cancer connection in non-Hodgkin's lymphoma: A genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res 69(8):3605-3613.
91. Ozturk N, Lee JH, Gaddameedhi S, Sancar S. 2009. Loss of cryptochrome reduces cancer risk in p53 mutant mice. Proc Natl Acad Sci U S A 106(8):2841-2846.
92. Eisele L, Prinz R, Klein-Hitpass L, Nückel H, Lowinski K, Thomale J, Moeller LC, Dührsen U, Dürig J. 2009. Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol 83(4):320-327.
93. Taniguchi H, Fernández AF, Setién F, Ropero S, Ballestar E, Villanueva A, Yamamoto H, Imai K, Shinomura Y, Esteller M. 2009. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res 69(21):8447-8454.
94. Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL. 2009. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One 4(3):e4798.
95. Knippschild U, Wolff S, Giamas G, Brockschmidt C, Wittau M, Würl PU, Eismann T, Stöter MM. 2005. The role of the casein kinase 1 (CK1) family in different signaling pathways linked to cancer development. Onkologie 28(10):508-514.
96. Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, Stevens RG, Hoffman A, Qin Q, Han X, Zheng T. 2007. Ala394Thr polymorphism in the clock gene NPAS2: A circadian modifier for the risk of non-Hodgkin's lymphoma. Int J Cancer 120(2):432-435.
97. Hoffman AE, Zheng T, Ba Y, Zhu Y. 2008. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response. Mol Cancer Res 6(9):1461-1468.
98. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, Wang X, Wang Z, Cornelissen-Guillaume G, Halberg FF. 2006. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci 97(7):589-596.
99. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang X, Wang Z, Ding JM. 2007. Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther 14(9):815-818.
100. Oda A, Katayose Y, Yabuuchi S, Yamamoto K, Mizuma M, Shirasou S, Onogawa T, Ohtsuka H, Yoshida H, Hayashi H, Rikiyama T, Kim H, Choe Y, Kim K, Son H, Motoi F, Egawa S, Unno M. 2009. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin. Anticancer Res 29(4):1201-1209.
101. Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ. 2009. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 117(2):423-431.
102. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. 2006. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22(3):375-382.
103. Suzuki T, Sato F, Kondo J, Liu Y, Kusumi T, Fujimoto K, Kato Y, Sato T, Kijima H. 2008. Period is involved in the proliferation of human pancreatic MIA-PaCa2 cancer cells by TNF-alpha. Biomed Res 29(2):99-103.
104. Sato F, Nagata C, Liu Y, Suzuki T, Kondo J, Morohashi S, Imaizumi T, Kato Y, Kijima H. 2009. Period1 (PER1) is an anti-apoptotic factor in human pancreatic and hepatic cancer cells. J Biochem 146(6):833-838.
105. Yang X, Wood PA, Ansell CM, Quiton DF, Oh EY, Du-Quiton J, Hrushesky WJ. 2009. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int 26(7):1323-1339.
106. Yang X, Wood PA, Ansell C, Hrushesky WJ, 2009. Circadian time-dependent tumor suppressor function of period genes. Integr Cancer Ther 8(4):309-316.
107. Nagel R, Clijsters L, Agami R. 2009. The miRNA-192/194 cluster regulates the Period gene family and the circadian clock. FEBS J 276(19):5447-5455.
108. Shimizu K, Sawazaki Y, Tanaka T, Asai T, Oku N. 2008. Chronopharmacologic cancer treatment with an angiogenic vessel-targeted liposomal drug. Biol Pharm Bull 31(1):95-98.
109. Okazaki F, Matsunaga N, Okazaki H, Utoguchi N, Suzuki R, Maruyama K, Koyanagi S, Ohdo S. 2010. Circadian rhythm of transferrin receptor 1 gene expression controlled by c-Myc in colon cancer-bearing mice. Cancer Res 70(15):6238-6246.